tiprankstipranks
Advertisement
Advertisement

REPL Stock Latest News

Replimune: Binary RP1 PDUFA Outcome and Funding Overhang Justify Hold Rating
RatingsReplimune: Binary RP1 PDUFA Outcome and Funding Overhang Justify Hold Rating
10d ago
REPL
FDA review process for accelerated approval narrows, less predictable, WSJ says
PremiumThe Fly
FDA review process for accelerated approval narrows, less predictable, WSJ says
23d ago
CAPR
IRON
Replimune price target raised to $14 from $13 at Piper Sandler
PremiumThe Fly
Replimune price target raised to $14 from $13 at Piper Sandler
2M ago
REPL
Replimune amends Hercules loan, strengthens funding runway
PremiumCompany Announcements
Replimune amends Hercules loan, strengthens funding runway
2M ago
8K
REPL
Replimune reports Q3 EPS (77c), consensus (82c)
PremiumThe Fly
Replimune reports Q3 EPS (77c), consensus (82c)
2M ago
REPL
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference
PremiumCompany AnnouncementsReplimune Highlights RP1, RP2 Progress Ahead of JPM Conference
2M ago
8K
REPL
Replimune Group Reports Increased Losses Amid R&D Expansion
Premium
Company Announcements
Replimune Group Reports Increased Losses Amid R&D Expansion
5M ago
REPL
Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position
Premium
Ratings
Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position
5M ago
REPL
Replimune reports Q2 EPS (90c), consensus (79c)
PremiumThe Fly
Replimune reports Q2 EPS (90c), consensus (79c)
5M ago
REPL
Replimune upgraded to Market Perform from Underperform at BMO Capital
PremiumThe Fly
Replimune upgraded to Market Perform from Underperform at BMO Capital
5M ago
REPL
Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
PremiumCompany Announcements
Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
5M ago
REPL
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
PremiumCompany Announcements
Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
5M ago
REPL
Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
PremiumCompany AnnouncementsReplimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
5M ago
REPL
Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
Premium
Company Announcements
Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
5M ago
REPL
Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
Premium
Company Announcements
Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
5M ago
REPL
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
PremiumCompany Announcements
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
5M ago
REPL
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
PremiumCompany Announcements
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
5M ago
BMY
REPL
Replimune Group’s RP1 Resubmission Boosts Approval Odds and Buy Rating
PremiumRatings
Replimune Group’s RP1 Resubmission Boosts Approval Odds and Buy Rating
5M ago
REPL
Replimune upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
Replimune upgraded to Buy from Neutral at H.C. Wainwright
5M ago
REPL
Genelux price target raised to $20 from $10 at Maxim
PremiumThe FlyGenelux price target raised to $20 from $10 at Maxim
5M ago
GNLX
REPL
Cautious Outlook on Replimune Group Amid FDA Uncertainties and Potential Risks
Premium
Ratings
Cautious Outlook on Replimune Group Amid FDA Uncertainties and Potential Risks
5M ago
REPL
Piper upgrades Replimune to Overweight on ‘very pleasant surprise’
Premium
The Fly
Piper upgrades Replimune to Overweight on ‘very pleasant surprise’
5M ago
REPL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >